Drupal.behaviors.print = function(context) {window.print();window.close();}>
Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion
February 09, 2012
Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma
May 3, 2012 / Gene Silencing News
Lundbeck, Debiopharm Join List of Pharmas Looking to RNAi
February 3, 2011 / Gene Silencing News
Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News
RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest
January 3, 2013 / Gene Silencing News
Silence Says Cash Runway Ends in Q3, Directors Have 'Uncertainty' About Additional Fundraising
March 22, 2012 / Gene Silencing News